Skip to main content
SpringerLink
Log in

Treatment of AIDS Anorexia-Cachexia Syndrome and Lipodystrophy

  • Chapter
Cachexia and Wasting: A Modern Approach

Abstract

Anorexia-cachexia syndrome [1] and lipodystrophy [2] [6] are two conditions frequently associated with the course of HIV infection. Under many circumstances, they can be included as components of a single disease, multifactorial in origin, leading to alterations of energetic metabolism and to body fat tissue modifications. The risk for the clinician is of only partially considering the two diseases, for which, until recently, a true definition [3] was lacking. The approach to therapy, due to the multifactorial origin, must be multidisciplinary, involving experts in nutrition, infectious diseases, physiology, gastroenterology, etc.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bruera E, Higginson I (1996) Cachexia-anorexia in cancer patients. Oxford University Press

    Google Scholar 

  2. Carr A, Samaras K, Burton S et al (1998) A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12:51–58

    Article  Google Scholar 

  3. Carr A, Emery S, Law M et al (2003) HIV lipodystrophy case definition study group. An objective case definition of lipodystrophy in HIV-infected adults. Lancet 361:726–735

    Article  PubMed  CAS  Google Scholar 

  4. Garg A, Misra A (2004) Lipodystrophies: rare disorders causing metabolic syndromes. Endocrinol Metab Clin North Am 33:305–331

    Article  PubMed  CAS  Google Scholar 

  5. Garg A (2004) Acquired and inherited lipodystrophies. N Engl J Med 350:1220–1234

    Article  PubMed  CAS  Google Scholar 

  6. Tien PC, Grunfeld C (2004) What is HIV-associated lipodystrophy? Defining fat distribution changes in HIV infection. Curr Opin Infect Dis 17:27–32

    Article  PubMed  Google Scholar 

  7. Ledru E, Christeff N, Patey O et al (2000) Alteration of tumor necrosis factor-alpha T-cell homeostasis following potent antiretroviral therapy: contribution to the development of immunodeficiency virusassociated lipodystrophy syndrome. Blood 95:3191–3198

    PubMed  CAS  Google Scholar 

  8. King AB (1990) Malnutrition in HIV infection: prevalence, etiology and management. PAACnotes 2:122–159

    Google Scholar 

  9. Kotler DP, Tierney AR, Francisco A et al (1989) The magnitude of body cell mass depletion determines the timing of death from wasting in AIDS. Am J Clin Nutr 50:444–447

    PubMed  CAS  Google Scholar 

  10. Watson RR (1994) Nutrition and AIDS. CRC Press, Boca Raton

    Google Scholar 

  11. Wanke CA, Silva M, Knox TA et al (2000) Weight loss and wasting remain common complications in individuals infected with human immunodeficiency virus in the era of highly active antiretroviral therapy. Clin Infect Dis 31:803–805

    Article  PubMed  CAS  Google Scholar 

  12. Ullrich R, Zeitz M, Heise W et al (1989) Small intestinal structure and function in patients infected with human immunodeficiency virus (HIV): evidence for HIV-induced enteropathy. Ann Intern Med 111:15–21

    PubMed  CAS  Google Scholar 

  13. Matsuyama T, Kobayashi N, Yamamoto N (1991) Cytokines and HIV infection: is AIDS a tumor necrosis factor disease? AIDS 5:1405–1417

    Article  PubMed  CAS  Google Scholar 

  14. Grunfeld C, Kotler DP (1992) Wasting in the Acquired Immunodeficiency Syndrome, Seminars in Liver Disease. Thieme Inc, New York

    Google Scholar 

  15. Center for Disease Control (1987) Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. MMWR Morb Mortal Wkly Rep 36(Suppl 1):3S–15S

    Google Scholar 

  16. Nahler BL, Chu SY, Newanyanwu C et al (1993) HIV wasting syndrome in the United States. AIDS 7:183–188

    Article  Google Scholar 

  17. Denning P, Chu SY, Hanson D et al (1994) The adult/adolescent spectrum disease (ASD) project group: HIV wasting syndrome in adults and adolescents with AIDS. 34th ICAAC, 4–7/10/1994, Orlando, Florida, p 114,abs 1135

    Google Scholar 

  18. Dworkin MS, Williamson JM; Adult/Adolescent Spectrum of HIV Disease Project (2003) Related AIDS wasting syndrome: trends, influence on opportunistic infections, and survival. J Acquir Immune Defic Syndr 33:267–273

    Google Scholar 

  19. Chlebowski RT, Grosvenor MB, Bernhard NH et al (1989) Nutritional status, gastrointestinal dysfunction, and survival in patients with AIDS. Am J Gastroenterol 84:1288–1293

    PubMed  CAS  Google Scholar 

  20. Scevola D, Barbarini G, Zambelli A et al (1989) Nutritional status in AIDS patients. 5th International Conference on AIDS, Montreal, Abstracts Book, p 465

    Google Scholar 

  21. Scevola D, Barbarini G, Zambelli A et al (1990) Evaluation and therapy of malnutrition in enteropathogenic AIDS. 6th International Conference on AIDS, San Francisco, California, Abstracts Book, p 168

    Google Scholar 

  22. Scevola D, Zambelli A, Bottari G et al (1991) Appetite stimulation and body weight gain with medroxyprogesterone acetate in AIDS anorexia and cachexia. Farmaci e Terapia 3:77–83

    Google Scholar 

  23. Scevola D, Barbarini G, Bottari G et al (1991) Prevalence, etiology and management of AIDS malnutrition. 7th International Conference on AIDS, Florence, Abstracts Book,WB 2169

    Google Scholar 

  24. Scevola D, Bottari G, Zambelli A et al (1992) Trattamento dietetico ed ormonale dei deficits nutrizionali nell’AIDS. Clin Dietol 19:127–140

    Google Scholar 

  25. Scevola D (1993) La cachessia nelle malattie infettive e neoplastiche. Edizioni Medico Scientifiche, Pavia

    Google Scholar 

  26. Scevola D, Bottari G, Faggi A et al (1994) Palliative care in infectious diseases. Eur J Pall Care 1:88–91

    Google Scholar 

  27. Anonymous (1989) Malnutrition and weight loss in patients with AIDS. Nutr Rev 11:354–356

    Google Scholar 

  28. Melchior JC, Salmon D, Rigaud D et al (1991) Resting energy expenditure is increased in stable, malnourished HIV-infected patients. Am J Clin Nutr 53:437–441

    PubMed  CAS  Google Scholar 

  29. Kotier DP, Tierney AR, Dilmanian FA et al (1991) Correlation between total body potassium and total body nitrogen in patients with acquired immunodeficiency syndrome. Clin Res 39:649A

    Google Scholar 

  30. Bogden JD, Baker H, Frank O et al (1990) Micronutrient status and HIV infection. Ann NY Acad Sci 587:189–195

    PubMed  CAS  Google Scholar 

  31. Coodley G (1990) Nutritional deficiency and AIDS. Ann Intern Med 113:807

    PubMed  CAS  Google Scholar 

  32. Coodley GO, Loveless MO, Merrill TM (1994) The HIV wasting syndrome: a review. J Acquir Immune Defic Syndr 7:681–694

    PubMed  CAS  Google Scholar 

  33. Baum M, Cassetti L, Bonvehi P et al (1994) Inadeguate dietary intake and altered nutrition status in early HIV-1 infection. Nutrition 10:16–20

    PubMed  CAS  Google Scholar 

  34. Timbo BB, Tollefson L (1994) Nutrition: a cofactor in HIV disease. J Am Diet Assoc 94:1019–1022

    Article  Google Scholar 

  35. Macallan DC, Noble C, Baldwin C et al (1995) Energy expenditure and wasting in human immunodeficiency virus infection. N Engl J Med 333:83–88

    Article  PubMed  CAS  Google Scholar 

  36. Kotier DP, Wang J, Pierson R (1985) Studies of body composition in patients with the acquired immunodeficiency syndrome. Am J Clin Nutr 42:1255–1265

    Google Scholar 

  37. Cahill GF (1979) Starvation in man. N Engl J Med 282:668–675

    Google Scholar 

  38. Brennen MF (1977) Uncomplicated starvation versus cancer cachexia. Cancer Res 37:2359–2364

    Google Scholar 

  39. Grunfeld C, Feingold KR (1992) Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med 5:329–337

    Google Scholar 

  40. Wolfe RR, Shaw JH, Durkot MJ (1985) Effect of sepsis on VLDL kinetics: responses in basal state and during glucose infusion. Am J Physiol 248:E732–E740

    PubMed  CAS  Google Scholar 

  41. Scevola D, Barbarini G, Bottari G et al (1990) Nutritional management of enteropathogenic human immunodeficiency virus infection. Eur J Gastroenterol Hepatol 2(Sl):S100–S101

    Google Scholar 

  42. Sharkey SJ, Sharkey KA, Sutherland LR et al (1992) Nutritional status and food intake in human immunodeficiency virus infection. GI/HIV Study Group. J Acquir Immune Defic Syndr 5:1091–1098

    PubMed  CAS  Google Scholar 

  43. Coodley GO, Loveless MO, Nelson HD, Coodley MK (1994) Endocrine dysfunction in the HIV wasting syndrome. J Acquir Immune Defic Syndr 7:46–51

    PubMed  CAS  Google Scholar 

  44. Hellerstein MK, Khan J, Mudie H, Viteri F (1990) Current approach to the treatment of human immunodeficiency virus-associated weight loss: pathophysiologic considerations and emerging management strategies. Semin Oncol 17(Suppl 9):17–33

    PubMed  CAS  Google Scholar 

  45. Tracey KJ, Morgello S, Koplin B et al (1990) Metabolic effects of cachectin/tumor necrosis factor are modified by site of production. J Clin Invest 86:2014–2024

    Article  PubMed  CAS  Google Scholar 

  46. Feingold KR, Soued M, Serio MK et al (1990) The effect of diet on tumor necrosis factor stimulation of hepatic lipogenesis. Metabolism 39:623–632

    Article  PubMed  CAS  Google Scholar 

  47. Hellerstein MK, Meydani SN et al (1989) Interleukin-1-induced anorexia in the rat. Influence of prostaglandins. J Clin Invest 84:228–235

    PubMed  CAS  Google Scholar 

  48. Langstein HN, Doherty GM, Fraker DL et al (1991) The role of interferon gamma and tumor necrosis factor in an experimental rat model of cancer cachexia. Cancer Res 51:2302–2306

    PubMed  CAS  Google Scholar 

  49. Carr A, Samaras K, Thorisdottir A et al (1999) Diagnosis, prediction and natural course of HIV protease inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus. Lancet 353:2093–2099

    Article  PubMed  CAS  Google Scholar 

  50. Safrin S, Grunfeld C (1999) Fat distribution and metabolic changes in patients with HIV infection. AIDS 13:2494–2505

    Article  Google Scholar 

  51. Nemechek PM, Polsky B, Gottleieb MS (2000) Treatment guidelines for HIV-associated wasting. Mayo Clin Proc 75:386–394

    PubMed  CAS  Google Scholar 

  52. Melchior JC, Salmon D, Rigaud D et al (1991) Resting energy expenditure is increased in stable, malnourished HIV-infected patients. Am J Clin Nutr 53:437–441

    PubMed  CAS  Google Scholar 

  53. Melchior JC, Raguin G, Boulier A et al (1993) Resting energy expenditure in human immunodeficiency virus infected patients: comparison between patients with and without secondary infection. Am J Clin Nutr 57:614–619

    PubMed  CAS  Google Scholar 

  54. Anonymous (1994) Position of The American Dietetic Association and the Canadian Dietetic Association: nutrition intervention in the care of persons with human immunodeficiency virus infection. J Am Diet Assoc 94:1042–1045

    Article  Google Scholar 

  55. Harris JA, Benedict FG (1919) A biometric study of basal metabolism in man. Washington DC Carnegie Institution, Washington DC, p 227

    Google Scholar 

  56. Udine LM (1990) Home nutritional support and AIDS. In: Proceedings of the American Society for Parenteral and Enterai Nutrition. Fourteenth Clinical Congress, January 28–31 San Antonio, Texas, pp 311–314

    Google Scholar 

  57. Wilmore DW (1991) Catabolic illness: strategies for enancing recovery. N Engl J Med 325:695–702

    Article  PubMed  CAS  Google Scholar 

  58. Tisdale MJ, Beck SA (1991) Inhibition of tumourinduced lipolysis in vitro and cachexia and tumour growth in vivo by eicosapentaenoic acid. Biochem Pharmacol 41:103–107

    Article  PubMed  CAS  Google Scholar 

  59. Scevola D, Oberto L, Bottari G, Faggi A (1995) Lipidi e malattie infettive. XII Congresso Nazionale ADI, Torino 16-18/11/1995, Abstracts Book, p 187

    Google Scholar 

  60. Beck SA, Tisdale MJ (1989) Nitrogen excretion in cancer cachexia and its modification by a high fat diet in mice. Cancer Res 49:3800–3804

    PubMed  CAS  Google Scholar 

  61. Tisdale MJ, Dhesi JK (1990) Inhibition of weight loss by omega-3 fatty acids in an experimental cachexia model. Cancer Res 50:5022–5026

    PubMed  CAS  Google Scholar 

  62. Fearon KC, Borland W, Preston T et al (1988) Cancer cachexia: influence of systemic ketosis on substrate levels and nitrogen metabolism. Am J Clin Nutr 47:42–48

    PubMed  CAS  Google Scholar 

  63. Kardinal CG, Loprinzi CL, Schaid DJ et al (1990) A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 65:2657–2662

    Article  PubMed  CAS  Google Scholar 

  64. Nobel RE (1969) Effect of cyproheptadine on appetite and weight gain in adults. JAMA 209:2054–2055

    Article  Google Scholar 

  65. Scevola D, Zambelli A, Bottari G et al (1991) Appetite stimulation and body weight gain with medroxyprogesterone acetate in AIDS anorexia and cachexia. Farmaci e Terapia 3:77–83

    Google Scholar 

  66. Scevola D, Parazzini F, Negri C, Moroni M (1995) Efficacy and safety of high-dose MPA treatment of AIDS cachexia: the Italian multicentre study. In: Proceedings of 4th Congress of the European Association for Palliative Care, Barcelona, December 6–9-1995, pp 443–447

    Google Scholar 

  67. Von Roenn JH (1994) Management of HIV-related body weight loss. Drugs 47:774–783

    Google Scholar 

  68. Scevola D, Bottari G, Oberto L et al (1995) A doubleblind-placebo controlled trial of megestrol acetate on caloric intake and nutritional status in AIDS cachexia. In: Proceedings of 4th Congress of European Association for Palliative Care, Barcelona, December 6–9-1995, pp 427–437

    Google Scholar 

  69. Tchekmedyian NS, Hichman M, Heber D (1991) Treatment of anorexia and weight loss with megestrol acetate in patients with cancer and aquired Immunodeficiency Syndrome. Semin Oncol 18:35–42

    PubMed  CAS  Google Scholar 

  70. Rondanelli M, Solerte SB, Fioravanti M et al (1997) Circadian secretory pattern of growth hormone, insulin-like growth factor type I, cortisol, adrenocorticotropic hormone, thyroid-stimulating hormone, and prolactin during HIV infection. AIDS Res Hum Retroviruses 14:1243–1249

    Google Scholar 

  71. Scevola D, Bottari G, Oberto L et al (1995) Megestrol acetate (MA) and growth hormone (rhGH) as combined therapy for AIDS cachexia. In: Proceedings of 4th Congress of European Association for Palliative Care, Barcelona, December 6–9-1995, pp 438–442

    Google Scholar 

  72. Douglas RG, Humberstone DA, Haystead A, Shaw JH (1990) Metabolic effects of recombinant human growth hormone: isotopic studies in the postabsorptive state during total parenteral nutrition. Br J Surg 77:785–790

    Article  PubMed  CAS  Google Scholar 

  73. Haller DG, Glick JG (1986) Progestational agents in advanced breast cancer: an overview. Semin Oncol 13:2–8

    PubMed  CAS  Google Scholar 

  74. Grunfeld C (1991) Mechanisms of wasting in infection and cancer: an approach to cachexia in AIDS. In: Kotler DP (ed) Gastrointestinal and nutritional manifestations of AIDS. Raven Press, New York, pp 207–229

    Google Scholar 

  75. Hellerstein MK, Kahn J, Mudie H, Viteri F (1990) Current approach to the treatment of human immunodeficiency virus-associated weight loss: pathophysiologic consideration and emerging management strategies. Semin Oncol 17:17–33

    PubMed  CAS  Google Scholar 

  76. Von Roenn JH, Murphy RI, Weber KM et al (1988) Megestrol acetate for treatment of cachexia associated with human immunodeficiency virus (HIV) infection. Ann Intern Med 109:840–841

    Google Scholar 

  77. Von Roenn JH, Armstrong D, Kotier DP et al (1994) Megestral acetate in patients with AIDS. Ann Intern Med 121:393–399

    Google Scholar 

  78. Von Roenn JH, Murphy RL, Wegener N (19901) Megestrol acetate for treatment of anorexia and cachexia associated with human immunodeficiency virus infection. Semin Oncol 17:13–16

    Google Scholar 

  79. Oster MH, Enders SR, Samuels SJ et al (1994) Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med 121:400–408

    PubMed  CAS  Google Scholar 

  80. Scevola D, Zambelli A, Bottari G et al (1991) Appetite stimulation and body weight gain with medroxyprogesterone acetate in AIDS anorexia and cachexia. Farmaci e Terapia 3:77–83

    Google Scholar 

  81. Vonn Roenn JH, Armstrong D, Kotler DP et al (1994) Megestrol acetate in patients with AIDS related cachexia. Ann Intern Med 121:393–399

    Google Scholar 

  82. Giacosa A, Fascio F, Sukkar SG et al (1993) Megestrolo e anoressia neoplastica. ADI Notiziario 11 Congresso Nazionale Nutrizione e Cancro, Suppl 2:68–69

    Google Scholar 

  83. Scevola D, Bottari G, Oberto L (1992) Changes in caloric intake, anthropometric parameters and TNF levels induced by megestrol acetate in AIDS patients. 8th International Conference on AIDS, Abstracts Book,p 133, PUB 7505

    Google Scholar 

  84. Lyons PM, Truswell AS, Mira M et al (1989) Reduction of food intake in the ovulatory phase of menstrual cycle. Am J Clin Nutr 49:1164–1168

    PubMed  CAS  Google Scholar 

  85. Bruera E, MacMillan K, Kuehm N et al (1990) A controlled trial of megestrol acetate on appetite, caloric intake, nutritional status and other symptoms in patients with advanced cancer. Cancer 66:1279–1282

    Article  PubMed  CAS  Google Scholar 

  86. Oster MH, Enders SR, Samuels SJ et al (1994) Megestrol acetate in cachectic patients with AIDS. Ann Intern Med 121:400–408

    PubMed  CAS  Google Scholar 

  87. Davidson MB (1987) Effect of growth hormone on carbohydrate and lipid metabolism. Endocr Rev 8:115–131

    PubMed  CAS  Google Scholar 

  88. Salomon F, Cuneo RC, Hesp R, Sonksen PH (1989) The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. N Engl J Med 321:1797–1803

    Article  PubMed  CAS  Google Scholar 

  89. Bengtsson BA, Eden S, Lonn L et al (1993) Treatment of adults with growth hormone (GH) deficiency with recombinant human GH. J Clin Endocrinol Metab 76:309–317

    Article  PubMed  CAS  Google Scholar 

  90. Cruz JM, Muss HB, Brockschmidt JK, Evans GW (1990) Weight changes in women with metastatic breast cancer treated with megestrol acetate: a comparison of standard versus high dose therapy. Semin Oncol 17(S9):63–67

    PubMed  CAS  Google Scholar 

  91. Tchkmedyian NS, Hichman M, Herber D (1991) Treatment of anorexia and weight loss with megestrol acetate in patients with cancer and acquired immunodeficiency syndrome. Semin Oncol 18:35–42

    Google Scholar 

  92. Grunfeld C, Feingold KR (1992) Metabolic disturbances and wasting in the acquired immunodeficiency syndrome. N Engl J Med 327:329–337

    Article  PubMed  CAS  Google Scholar 

  93. Kotier DP, Wang J, PiersonJr RN (1985) Body composition studies in patients with the acquired immunodeficiency syndrome. Am J Clin Nutr 42:1255–1265

    Google Scholar 

  94. Kotler DP, Tiernay AR, Wang J, PiersonJr RN (1989) Magnitude of body cell mass depletion and the timing of death from wasting in AIDS. Am J Clin Nutr 50:444–447

    PubMed  CAS  Google Scholar 

  95. Scevola D (1993) La cachessia nelle malattie infettive e neoplastiche. Tipografia Viscontea, Pavia, Italy

    Google Scholar 

  96. Mulligan K, Grunfeld C, Hellerstein MK et al (1993) Anabolic effects of recombinant human growth hormone in patients wiyh wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 77:956–962

    Article  PubMed  CAS  Google Scholar 

  97. Krentz AJ, Koster FT, Crist DM et al (1993) Anthropometric, metabolic and immunological effects of recombinant human growth hormone in AIDS and AIDS-related complex. J Acquir Immune Defic Syndr 19:245–251

    Google Scholar 

  98. Rudman D, Feller AG, Nagraj HS et al (1990) Effects of human growth hormone in men over 60 years. N Engl J Med 323:1–6

    Article  PubMed  CAS  Google Scholar 

  99. Benavides S, Nahata MC (2004) Pharmacologic therapy for HIV-associated lipodystrophy. Ann Pharmacother 38:448–457

    Article  PubMed  CAS  Google Scholar 

  100. Ross R, Dagnone D, Jones PJ et al (2000) Reduction in obesity and related comorbid conditions after diet-induced weight loss or exercise-induced weight loss in men. A randomized, controlled trial. Ann Intern Med 133:92–103

    PubMed  CAS  Google Scholar 

  101. Moyle G, Baldwin C, Phillipot M (2001) Managing metabolic disturbances and lipodystrophy: diet, exercise, and smoking advice. AIDS Read 11:589–592

    PubMed  CAS  Google Scholar 

  102. Hadigan C, Jeste S, Anderson EJ et al (2001) Modifiable dietary habitus and their relation to metabolic abnormalities in men and women with human immunodeficiency virus infection and fat redistribution. Clin Infect Dis 33:710–717

    Article  PubMed  CAS  Google Scholar 

  103. Roubenoff R, Schmitz H, Bairos L et al (2002) Reduction of abdominal obesity in lipodystrophy associated with immunodeficiency virus infection by means of diet and exercise: case report and proof of principle. Clin Infect Dis 34:390–393

    Article  PubMed  Google Scholar 

  104. Barrios A, Blanco F, Garcia-Benayas T et al (2002) Effect of dietary intervention on highly active antiretroviral therapy related dislipemia. AIDS 16:2079–2081

    Article  PubMed  Google Scholar 

  105. Scevola D, DiMatteo A, Lanzarini P et al (2003) Effect of exercise and strength training on cardiovascular status in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 17(S1):123–129

    Google Scholar 

  106. Scevola D, DiMatteo A, Giglio O et al (2004) Guidelines for the prevention of cardiovascular risk in HIV-infected patients treated with antiretroviral drugs. HIV&AIDS Review 3:177–184

    Google Scholar 

  107. McCarty MF (2003) Iatrogenic lipodystrophy in HIV patients. The need for very low fat diets. Med Hypotheses 61:561–566

    Article  PubMed  CAS  Google Scholar 

  108. McComsey G, Lederman M (2002) High doses of riboflavin and thiamine may help secondary prevention of hyperlactatemia. AIDS Read 12:222–224

    PubMed  Google Scholar 

  109. De la Asuncion J, Del Olmo M, Sastre J et al (1998) AZT treatment induces molecular and ultrastructural oxidative damage to muscle mitochondria. Prevention by antioxidant vitamins. J Clin Invest 102:4–9

    PubMed  Google Scholar 

  110. Paulik M, Lancaster M, Croom D et al (2000) Antioxidant rescue NRTI-induced metabolic changes in AKR/J mice. Antivir Ther 5:6–7

    Google Scholar 

  111. Fouty B, Frerman F, Reves R (1998) Riboflavin to treat nucleoside analogue-induced lactic acidosis. Lancet 352:291–292

    Article  PubMed  CAS  Google Scholar 

  112. Brinkman K, Vrouenrats S, Kauffman R et al (2000) Treatment of nucleoside reverse transcriptase inhibitor-induced lactic acidosis. AIDS 14:2801–2802

    Article  PubMed  CAS  Google Scholar 

  113. Luzzati R, Del Bravo P, Di Perri Get al (1999) Riboflavin and severe lactic acidosis. Lancet 353:901–902

    Article  PubMed  CAS  Google Scholar 

  114. Schramm C, Wanitschke R, Galle P (1999) Thiamine for the treatment of nucleoside analogueinduced severe lactic acidosis. Eur J Anaesthesiol 16:733–735

    Article  PubMed  CAS  Google Scholar 

  115. Gold D, Cohen B (2001) Treatment of mitochondrial cytopathies. Semin Neurol 21:309–325

    Article  PubMed  CAS  Google Scholar 

  116. Claessens Y, Cariou A, Chiche J et al (2000) L-carnitine as a treatment of life-threatening lactic acidosis induced by nucleoside analogues. AIDS 14:472–473

    Article  PubMed  CAS  Google Scholar 

  117. Scevola D, Oberto L, Bottari G, Faggi A (1995) Lipidi e Malattie Infettive. XII Congresso Nazionale ADI. Torino 16-18/11/1995, Abstracts Book,p 187

    Google Scholar 

  118. Scevola D, Bottari G, Oberto L, Faggi A (1996) AIDS cachexia: basics and treatment. In: Ruf B, Pohle HD, Goebel FD, L’age M (eds) HIV-Infektion, Pathogenese, Diagnostik und Therapie. Sociomedico Verlag, Graefelfing, pp 281–327

    Google Scholar 

  119. Scevola D, Bottari G, Oberto L et al (1996) Problemi nutrizionali del paziente AIDS e strategie terapeutiche. Quaderni di Cure Palliative S 1:51–64

    Google Scholar 

  120. Schwartz RS, Shuman WP, Larson V et al (1991) The effect of intensive endurance exercise training on body fat distribution in young and older men. Metabolism 40:545–551

    Article  PubMed  CAS  Google Scholar 

  121. Roubenoff R, McDermott A, Weiss L et al (1999) Short-term progressive resistance training increases strength and lean body mass in adults infected with human immunodeficiency virus. AIDS 13:231–239

    Article  PubMed  CAS  Google Scholar 

  122. Roubenoff R, Weiss L, McDermott A et al (1999) A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution. AIDS 13:1373–1375

    Article  PubMed  CAS  Google Scholar 

  123. Jaque S, Schroeder E, Azen S et al (2002) Regional body composition changes during anabolic therapy. Clin Exerc Physiol 4:50–59

    Google Scholar 

  124. Saint-Marc T, Touraine JL (1999) Effects of metformin on insulin resistence and central adiposity in patients receiving effective protease inhibitor therapy. AIDS 13:1000–1002

    Article  PubMed  CAS  Google Scholar 

  125. Hadigan C, Corcoran C, Basgoz N et al (2000) Metformin in the treatment of HIV lipodystrophy sindrome: a randomized controlled trial. JAMA 284:472–477

    Article  PubMed  CAS  Google Scholar 

  126. Mulligan K, Grunfeld C, Hellerstein MK et al (1993) Anabolic effects of recombinant growth hormone in patients with wasting associated with human immunodeficiency virus infection. J Clin Endocrinol Metab 77:956–962

    Article  PubMed  CAS  Google Scholar 

  127. Schambelan M, Mulligan K, Grunfeld C et al (1996) Recombinant human growth hormone in patients with HIV-associated wasting: a randomized, placebo-controlled trial. Serostim Study Group. Ann Intern Med 125:873–882

    PubMed  CAS  Google Scholar 

  128. Torres RA, Unger KW, Cadman JA, Kassous JY (1999) Recombinant human growth hormone improves truncal adiposity and ‘buffalo humps’ in HIV-positive patients on HAART. AIDS 13:2479–2481

    Article  PubMed  CAS  Google Scholar 

  129. Wanke C, Gerrior J, Kantaros J et al (1999) Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 13:2099–2103

    Article  PubMed  CAS  Google Scholar 

  130. Schwarz JM, Mulligan K, Lee J et al (2002) Effects of recombinant human growth hormone on hepatic lipid and carbohydrate metabolism in HIV-infected patients with fat accumulation. J Clin Endocrinol Metab 87:942

    Article  PubMed  CAS  Google Scholar 

  131. Koutkia P, Canavan B, Breu J et al (2004) Growth hormone-releasing hormone in HIV-infected men with lipodystrophy: a randomized controlled trial. JAMA 292:210–218

    Article  PubMed  CAS  Google Scholar 

  132. Zhang Y, Proenca R, Maffei M et al (1994) Positional cloning of the mouse obese gene and human homologue. Nature 372:425–432

    Article  PubMed  CAS  Google Scholar 

  133. Halaas JL, Gajiwala KS, Maffei M et al (1995) Weightreducing effects of the plasma protein encoded by the obese gene. Science 269:543–546

    Article  PubMed  CAS  Google Scholar 

  134. Ahima RS, Prabakaran D, Mantzoros C et al (1996) Role of leptin in the neuroendocrine response to fasting. Nature 382:250–252

    Article  PubMed  CAS  Google Scholar 

  135. Ahima RS, Flier JS (2000) Leptin. Annu Rev Physiol 62:413–437

    Article  PubMed  CAS  Google Scholar 

  136. Friedman JM, Halaas JL (1998) Leptin and the regulation of body weight in mammals. Nature 395:763–770

    Article  PubMed  CAS  Google Scholar 

  137. Friedman JM (2004) Modern science versus the stigma of obesity. Nat Med 10:563–569

    Article  PubMed  CAS  Google Scholar 

  138. Faggioni R, Feingold KR, Grunfeld C (2001) Leptin regulation of the immune response and the immunodeficiency of malnutrition. FASEB J 15:2565–2571

    Article  PubMed  CAS  Google Scholar 

  139. Spiegelman BM, Flier JS (2001) Obesity and the regulation of energy balance. Cell 104:531–543

    Article  PubMed  CAS  Google Scholar 

  140. Oral EA, Ruiz E, Andewelt A et al (2002) Effect of leptin replacement on pituitary hormone regulation in patients with severe lipodystrophy. J Clin Endocrinol Metab 87:3110–3117

    Article  PubMed  CAS  Google Scholar 

  141. McDuffie JR, Riggs PA, Calis K et al (2004) Effects of exogenous leptin on satiety and satiation in patients with lipodystrophy and leptin insufficiency. J Clin Endocrinol Metab 89:4258–4263

    Article  PubMed  CAS  Google Scholar 

  142. Moran SA, Patten N, Young JR et al (2004) Changes in body composition in patients with severe lipodystrophy after leptin replacement therapy. Metabolism 53:513–519

    Article  PubMed  CAS  Google Scholar 

  143. Moyle G, Baldwin C (2000) Switching from a PIbased to a Pi-sparing regimen for management of metabolic or clinical fat redistribution. AIDS Read 10:479–485

    PubMed  CAS  Google Scholar 

  144. Vigoureux C, Gharakhanian S, Salhi Y et al (1999) Adverse metabolic disorders during highly active antiretroviral treatments (HAART) of HIV disease. Diabetes Metab 25:383–392

    Google Scholar 

  145. Behrens GM, Stoll M, Schmidt RE (2000) Lipodystrophy syndrome in HIV infection: what is it, what causes it and how can it be managed? Drug Saf 23:57–76

    Article  PubMed  CAS  Google Scholar 

  146. Mallal SA, John M, Moore CB et al (2000) Contribution of nucleoside analogue revers transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 14:1309–1316

    Article  PubMed  CAS  Google Scholar 

  147. Kakuda TN (2000) Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity. Clin Ther 22:685–708

    Article  PubMed  CAS  Google Scholar 

  148. Carr A, Workman C, Smith DE et al (2002) Abacavir substitution for nucleoside analogs in patients with lipoatrophy. JAMA 288:207–215

    Article  PubMed  CAS  Google Scholar 

  149. McComsey GA, Ward DJ, Hessenthaler SM et al (2004) Improvement in lipoatrophy associated with highly active antiretroviral therapy in human immunodefiency virus-infected patients switched from stavudine to abacavir or zidovudine: the results of the TARHEEL study. Clin Infect Dis 38:263–270

    Article  PubMed  CAS  Google Scholar 

  150. Martin A, Smith DE, Carr A et al (2004) Reversibility of lipoatrophy in HIV-infected patients 2 years after switching from a thymidine analogue to abacavir: the MITOS Extension Study. AIDS 18:1029–1036

    Article  PubMed  CAS  Google Scholar 

  151. Strauch B, Baum T, Robbins N (2004) Treatment of human immunodeficiency virus-associated lipodystrophy with dermafat graft transfer to the malar area. Plast Reconstr Surg 113:363–370

    Article  PubMed  Google Scholar 

  152. Connolly N, Manders E, Riddler S (2004) Suctionassisted lilectomy for lipodystrophy. AIDS Res Hum Retroviruses 20:813–815

    Article  PubMed  Google Scholar 

  153. Amerd P, Saint-Marc T, Katz P (2000) The effects of polylactic acid as therapy for lipodystrophy of the face. Antivir Ther 5(Suppl 5):76

    Google Scholar 

  154. Moyle G, Baldwin C (2002) Management of morphologic changes during antiretroviral therapy: insights from etiology. HIV/AIDS Update 2002, iMedOptions, LLC

    Google Scholar 

  155. Ponce-de-Leon S, Iglesias M, Ceballos J et al (1999) Liposuction for protease-inhibitor associated lipodystrophy. Lancet 353:1244

    Article  PubMed  CAS  Google Scholar 

  156. Wolffort FG, Cetrulo CL, Nevarre DR (1999) Suction-assisted lipectomy for lipodystrophy syndromes attributed to HIV-protease inhibitor use. Plast Reconstr Surg 104:1814–1820

    Article  Google Scholar 

  157. Henry K, Melroe H, Huebesh J et al (1999) Experience with the National Cholesterol Education Program (NCEP) guidelines for the identification and treatment of protease inhibitor related lipid abnormalities: results of a prospective study. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Abstract 671

    Google Scholar 

  158. Grunfeld C, Feingold KR (1992) Metabolic disturbances and wasting in the acquired immunodeficency syndrome. N Engl J Med 5:329–337

    Google Scholar 

  159. Lonergan JT, Havlir D, Barber E, Mathews WC (2001) Incidence and outcome of hyperlactatemia associated with clinical manifestations in HIV-infected adults receiving NRTI-containing regimens. 8th Conference on Retroviruses and Opportunistic Infections, February 4–8-2001, Chicago, Abstract 624

    Google Scholar 

  160. Johnson JA, Albu JB, Engelson ES et al (2004) Increased systemic and adipose tissue cytokines in patients with HIV-associated lipodystrophy. Am J Physiol Endocrinol Metab 286:E261–E271

    Article  PubMed  CAS  Google Scholar 

  161. Scevola D, Di Matteo A, Uberti F et al (2000) Reversal of cachexia in patients treated with potent antiretroviral therapy. AIDS Read 10:365–375

    PubMed  CAS  Google Scholar 

  162. Henry K, Zackin R, Dube M et al (2001) Metabolic status and cardiovascular disease risk for a cohort of HIV-1-infected persons durably suppressed on an indinavir-containing regimen (ACTG 372A). Program and abstracts of the 8th Conference on Retroviruses and Opportunistic Infections, February 4–8-2001, Chicago, Abstract 656

    Google Scholar 

  163. Melchior JC, Salmon D, Rigaud D et al (1991) Resting energy expenditure is increased in stable, malnourished HIV-infected patients. Am J Clin Nutr 53:437–441

    PubMed  CAS  Google Scholar 

  164. Grunfeld C, Pang M, Shimizu L et al (1992) Resting energy expenditure, caloric intake and short-term weight change in human immunodeficiency virus infection and the acquired immuno-deficiency syndrome. Am J Clin Nutr 55:455–460

    PubMed  CAS  Google Scholar 

  165. Shevitz AH (2000) Resting energy expenditure in the HAART era. AIDS Read 10:539–544

    PubMed  CAS  Google Scholar 

  166. Anonymous (1986) Use and interpretation of anthropometric indicators of nutritional status. WHO Working Group. Bulletin of the WHO 64:929–941

    Google Scholar 

  167. Kotler DP, Rosenbaum K, Wang J, Pearson RN (1999) Studies of body composition and fat distribution in HIV-infected and control subjects. J Acquir Immune Defic Syndr Hum Retrovirol 20:228–237

    PubMed  CAS  Google Scholar 

  168. Scevola D (1993) La cachessia nelle malattie infettive e neoplastiche. Edizioni Medico Scientifiche, Pavia

    Google Scholar 

  169. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (2001) Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486–2497

    Article  Google Scholar 

  170. Scevola D, Di Matteo A, Lanzarini P et al (2003) Effect of exercise and strength training on cardiovascular status in HIV-infected patients receiving highly active antiretroviral therapy. AIDS 17(Suppl 1):S123–S129

    PubMed  Google Scholar 

  171. Volberding PA, Murphy RL, Barbara G et al (2003) The Pavia consensus statement. AIDS 17(Suppl l):S170–S179

    PubMed  Google Scholar 

  172. Dubé MP, Stein JH, Aberg JA et al (2003) Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HlV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS clinical trials group. Clin Infect Dis 37:613–627

    Article  PubMed  Google Scholar 

  173. Barrios A, Blanco F, Garcia-Benayas T et al (2002) Effect of dietary intervention on highly active antiretroviral therapy-related dyslipemia. AIDS 16:2079–2081

    Article  PubMed  Google Scholar 

  174. Von Roenn JH (1994) Management of HIV-related body weight loss. Drugs 47:774–783

    Google Scholar 

  175. Scevola D, Bottari G, Zambelli A et al (1992) Trattamento dietetico ed ormonale dei deficit nutrizionali nell’AIDS. Clin Dietol 19:127–140

    Google Scholar 

  176. Bernasconi E (1999) Metabolic effects of protease inhibitor therapy. AIDS Read 9:254–269

    PubMed  CAS  Google Scholar 

  177. Tisdale M, Beck SA (1991) Inhibition of tumour induced lipolysis in vitro and cachexia and tumour growth in vivo by eicosapentaenoic acid. Biochem Pharmacol 41:103–107

    Article  PubMed  CAS  Google Scholar 

  178. Kardinal CG, Loprinzi CL, Schaid DJ et al (1990) A controlled trial of cyproheptadine in cancer patients with anorexia and/or cachexia. Cancer 65:2657–2662

    Article  PubMed  CAS  Google Scholar 

  179. Scevola D, Zambelli A, Bottari G et al (1991) Appetite stimulation and body weight gain with medroxyprogesterone acetate in AIDS anorexia and cachexia. Farmaci e Terapia 3:77–83

    Google Scholar 

  180. Scevola D, Parazzini F, Negri C, Moroni M (1995) Efficacy and safety of high-dose MPA treatment of AIDS cachexia: the Italian multicentre study. 4th Congress of the European Association for Palliative Care, Barcelona, December 6–9-1995, Abstracts Book, pp 443–447

    Google Scholar 

  181. Scevola D, Bottari G, Oberto L et al (1995) A doubleblind-placebo controlled trial of megestrol acetate on caloric intake and nutritional status in AIDS cachexia. 4th Congress of European Association for Palliative Care, Barcelona, December 6–9-1995, Abstracts Book, pp 427–437

    Google Scholar 

  182. Rondanelli M, Solerte SB, Fioravanti M et al (1997) Circadian secretory pattern of growth hormone, insulin-like growth factor type I, cortisol, adrenocorticotropic hormone, thyroid-stimulating hormone, and prolactin during HIV infection. AIDS Res Hum Retroviruses 14:1243–1249

    Article  Google Scholar 

  183. Scevola D, Bottari G, Oberto L et al (1995) Megestrol acetate (MA) and growth hormone (rHGH) as combined therapy for AIDS cachexia. 4th Congress of European Association for Palliative Care, Barcelona, December 6–9-1995, Abstracts Book, pp 438–442

    Google Scholar 

  184. Wanke C, Gerrior J, Kantaros J et al (1999) Recombinant human growth hormone improves the fat redistribution syndrome (lipodystrophy) in patients with HIV. AIDS 13:2099–2103

    Article  PubMed  CAS  Google Scholar 

  185. Henry K, Melroe H, Huebesh J et al (1999) Experience with the National Cholesterol Education Program (NCEP) guidelines for the identification and treatment of protease inhibitor related lipid abnormalities: results of a prospective study. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Abstract 671

    Google Scholar 

  186. Saint-Marc T, Touraine JL (1999) Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor (PI). 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Abstract 672

    Google Scholar 

  187. Walli RK, Michl GM, Muhlbayer D et al (2000) Effects of troglitazone on insulin sensitivity in HIV-infected patients with protease inhibitor-associated diabetes mellitus. Res Exp Med (Ber) 199:253–262

    Article  CAS  Google Scholar 

  188. Calmy A, Hirschel B, Hans D et al (2003) Glitazones in lipodystrophy syndrome induced highly active antiretroviral therapy. AIDS 17:770–772

    Article  PubMed  Google Scholar 

  189. Carr A, Workman C, Carey D et al (2004) No effect of rosiglitazone for treatment of HIV-1 lipoatrophy: randomised, double-blind, placebo-controlled trial. Lancet 363:429–438

    Article  PubMed  CAS  Google Scholar 

  190. Torres R, Unger K (1999) The effect of recombinant human growth hormone on protease-inhibitor associated fat maldistribution syndrome. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, Abstract 675

    Google Scholar 

  191. Strawford A, Barbieri T, Parks E et al (1999) Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss. JAMA 281:1282–1290

    Article  PubMed  CAS  Google Scholar 

  192. Amsterdam EA (1977) Exercise in cardiovascular health and disease. Yorke Medical Books, New York

    Google Scholar 

  193. Smith BA, Neidig JL, Nickel JT et al (2001) Aerobic exercise: effects on parameters related to fatigue, dyspnea, weight and body composition in HIV-infected adults. AIDS 15:693–701

    Article  PubMed  CAS  Google Scholar 

  194. Montoye HJ (1975) Physical activity and health: an epidemiologic study of an entire community. Englewood Cliffs, NJ Prentice-Hall

    Google Scholar 

  195. Katch FI, Freedson PS, Jones CA et al (1985) Evaluation of acute cardiorespiratory responses to hydraulic resistance exercise. Medicine and Science in Sports and Exercise 17:168–173

    PubMed  CAS  Google Scholar 

  196. Crow RS, Rantahargiu PM, Prineas RJ et al (1986) Risk factors, exercise fitness and electrocardiographic response to exercise in 12,866 men at risk of symptomatic coronary heart disease. Am J Cardiol 57:1075–1082

    Article  PubMed  CAS  Google Scholar 

  197. Barbara, Giuseppe; Boccara, Franck (eds) (2005) Cardiovascular disease in AIDS. Springer, Milan

    Google Scholar 

  198. Pollock M, Gaesser G, Butcher J et al (1998) The recommended quantity and quality of exercise for developing and maintaining cardiorespiratory and muscular fitness, and flexibility in healthy adults. Med Sci Sports Exerc 30:975–991

    Article  Google Scholar 

  199. Stringer WW, Berezovskaya M, O’Brien WA et al (1998) The effect of exercise training on aerobic fitness, immune indices, and quality of life in HIV+ patients. Med Sci Sports Exerc 30:11–16

    PubMed  CAS  Google Scholar 

  200. Grinspoon S, Carr A (2005) Cardiovascular risk and body-fat abnormalities in HIV-infected adults. N Engl J Med 352:48–62

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Infectious Diseases, IRCCS S.Matteo Polyclinic, University of Pavia, Pavia, Italy

    Daniele Scevola & Omar Giglio

  2. Department of Surgery, Section of Plastic Surgery, IRCCS Maugeri Foundation, University of Pavia, Pavia, Italy

    Silvia Scevola

Authors
  1. Daniele Scevola
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Omar Giglio
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Silvia Scevola
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Medical Oncology, University of Cagliari, Cagliari, Italy

    Giovanni Mantovani

  2. Department of Clinical Cardiology, Imperial College, NHLI, London, UK

    Stefan D. Anker

  3. Department of Cardiology Charité, Applied Cachexia Research, Campus Virchow-Klinikum, Berlin, Germany

    Stefan D. Anker

  4. Department of Behavioral Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan

    Akio Inui

  5. GRECC, VA Medical Center and Division of Geriatric Medicine, Saint Louis University, St. Louis, MO, USA

    John E. Morley

  6. Department of Clinical Medicine, University of Rome, La Sapienza, Rome, Italy

    Filippo Rossi Fanelli

  7. Department of Infectious Diseases, IRCCS S.Matteo Polyclinic, University of Pavia, Pavia, Italy

    Daniele Scevola

  8. Bone Marrow and Blood Stem Cell Transplantation Program, Center for Lymphoma and Myeloma, New York Presbyterian Hospital/Weill Medical Center, New York, NY, USA

    Michael W. Schuster

  9. Department of Medicine-Geriatrics, University of New York at Stony Brook VAMC, Northport, NY, USA

    Shing-Shing Yeh

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag Italia

About this chapter

Cite this chapter

Scevola, D., Giglio, O., Scevola, S. (2006). Treatment of AIDS Anorexia-Cachexia Syndrome and Lipodystrophy. In: Mantovani, G., et al. Cachexia and Wasting: A Modern Approach. Springer, Milano. https://doi.org/10.1007/978-88-470-0552-5_41

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-0552-5_41

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-88-470-0471-9

  • Online ISBN: 978-88-470-0552-5

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation